Coronavirus stocks: 3 unloved shares I think could make you rich

These shares have fallen in the coronavirus stock market crash, but buying today could put you ahead of the market, says Roland Head.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

A stock market crash often provides us with great opportunities to buy quality shares at bargain prices. This year, I’m calling these coronavirus stocks – businesses that have been hit by Covid-19 but that should make strong recoveries.

I reckon that buying these shares today could help you beat the market for many years to come.

You may wonder why I’m ignoring coronavirus vaccine stocks like Synairgen, which has risen by 500% in two weeks. The reason for this is simply that I think it’s too late.

Synairgen and its rivals are now priced for huge success, but at least some of them will disappoint investors. When that happens, their share prices could crash.

Coronavirus stock #1: Foxtons

Estate agents have been hit hard by the pandemic. London-focused Foxtons (LSE: FOXT) is no exception. Foxtons’ share price has fallen by 60% from its February high, but I think the shares are now looking too cheap.

The latest report from the company tells me that Foxtons is very unlikely to run out of cash, even if we see a long housing market slump. Net cash was £40.5m at the end of June and the company’s operations generated underlying positive cash flow of £4.6m during the half year.

Of course, business isn’t good at the moment. Revenue fell by 20% during the half year and the group reported an accounting loss of £4.3m for the period. But housing activity is returning and Foxtons also has a stable lettings business. Over time, I’m confident the shares will recover. I think Foxtons’ share price could double over the next few years.

Coronavirus stock #2: AG Barr

Soft drinks are generally seen as a defensive product. Demand doesn’t change much, even during a recession. However, sales can suffer when every pub, café, and restaurant in the country is closed, as we saw during lockdown.

What’s interesting about Irn-Bru maker AG Barr (LSE: BAG) is that according to the firm, only 10% of sales are made to the hospitality trade. More than 80% of sales are impulse buys or are made through supermarkets. As a result of this sales profile, the company still achieved 88% of last year’s sales during the April-June lockdown period.

Revenue for the six months to 25 July is expected to be down by just 8%. Profits for the full year are expected to be lower, but I don’t see this as a concern. AG Barr has been a reliable performer for many years. I’m sure it will recover. With the stock trading at an eight-year low, I’d buy today.

Coronavirus stock #3: An overlooked insurance play?

My final choice is motor insurance company Sabre Insurance (LSE: SBRE). Sabre floated on the FTSE 250 in 2017 and specialises in insuring drivers who attract high premiums. It’s a very profitable business that I believe is likely to be a good dividend stock.

Numbers released today show that profitability has remained strong during the first half of this year. Although sales were down, disciplined pricing helped to support the group’s profit margins.

Cash generation remains strong and Sabre has now restored its dividend. Shareholders will receive a total payout of 9.5p per share for the first half of the year. Analysts expect a total payout of 19p this year, giving the stock a forecast yield of 6.8%. I rate Sabre as a dividend stock to buy today.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended AG Barr. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »